Department of Metabolism, Digestion and Reproduction, Division of Digestive Diseases, Section of Hepatology, St Mary's Hospital, NHS Trust, Imperial College London, United Kingdom.
Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
Clin Gastroenterol Hepatol. 2023 Mar;21(3):713-722.e3. doi: 10.1016/j.cgh.2022.03.048. Epub 2022 Apr 15.
BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is a growing concern in the aging population with human immunodeficiency virus (HIV). Screening for NAFLD is recommended in patients with metabolic risk factors or unexplained transaminitis. This study aimed to prospectively assess the prevalence and associated factors of liver steatosis and advanced fibrosis (AF) in HIV-monoinfected patients at risk of NAFLD.
We conducted a multicenter study in HIV-monoinfected patients, nonexcessive drinkers with metabolic syndrome, and/or persistently elevated liver enzymes, and/or clinical lipodystrophy. All participants had magnetic resonance imaging proton density fat fraction (MRI-PDFF), Fibroscan/controlled attenuation parameter (CAP), and cytokine and genetic analysis.
From March 2014 to November 2015, we enrolled 442 participants and analyzed 402: male (85%); median age, 55 years (interquartile range [IQR], 50-61 years); body mass index, 27.0 kg/m (IQR, 23.6-28.7 kg/m); metabolic syndrome (67%); and CD4 cell count, 630/mm (IQR, 510-832/mm). Overall 257 of 402 (64%) had NAFLD (MRI-PDFF ≥5%). Among them, 11.3% had a liver stiffness ≥9.6 kPa, suggestive of AF. Multivariable analysis identified 7 factors of steatosis: high CD4-cell count (odds ratio [OR], 4.04; 95% confidence interval [CI], 1.92-8.51), high leptin level (OR, 2.12; 95% CI, 1.14-3.93), non-CC PNPLA3s738409 genetic polymorphism (OR, 1.92; 95% CI, 1.11-3.33), low high-density lipoprotein (OR, 1.83; 95% CI, 1.03-3.27), high triglycerides (OR, 1.48; 95% CI, 1.18-1.84), elevated alanine transaminase (OR, 1.23; 95% CI, 1.16-1.31), and hyper ferritinemia (OR, 1.05; 95% CI, 1.03-1.07). Two factors were associated with AF: high body mass index (OR, 1.23 ; 95% CI, 1.07-1.42 ; P = .005, and elevated aspartate aminotransferase (OR, 1.03; 95% CI, 1.01-1.05; P = .001). Using MRI-PDFF as a reference, CAP (best cutoff, 280 dB/m) had good accuracy (area under the receiver operating characteristic curve = 0.86; 95% CI, 0.82-0.90) for the diagnosis of moderate to severe steatosis.
In a large cohort of HIV-moninfected patients at risk of NAFLD, steatosis is present in two-thirds of cases, and around 10% have AF. The CAP technique is accurate for screening steatosis in this population.
非酒精性脂肪性肝病(NAFLD)是人类免疫缺陷病毒(HIV)感染人群中日益受到关注的问题。建议对存在代谢危险因素或不明原因转氨酸升高的患者进行 NAFLD 筛查。本研究旨在前瞻性评估代谢风险因素或不明原因转氨酸升高的 HIV 单一感染者中 NAFLD 的患病率及其相关因素。
我们进行了一项多中心研究,纳入了 HIV 单一感染者、代谢综合征且/或持续转氨酸升高、且/或存在临床脂肪营养不良的非过量饮酒者。所有参与者均进行了磁共振成像质子密度脂肪分数(MRI-PDFF)、Fibroscan/受控衰减参数(CAP)、细胞因子和基因分析。
2014 年 3 月至 2015 年 11 月,我们共纳入 442 名参与者,分析了 402 名参与者的数据:男性(85%);中位年龄 55 岁(四分位距 [IQR],50-61 岁);体重指数 27.0 kg/m(IQR,23.6-28.7 kg/m);代谢综合征(67%);CD4 细胞计数 630/mm(IQR,510-832/mm)。402 名参与者中 257 名(64%)患有 NAFLD(MRI-PDFF≥5%)。其中,11.3%的患者肝硬度≥9.6 kPa,提示存在 AF。多变量分析确定了 7 个与脂肪变性相关的因素:高 CD4 细胞计数(比值比 [OR],4.04;95%置信区间 [CI],1.92-8.51)、高瘦素水平(OR,2.12;95%CI,1.14-3.93)、非 CC PNPLA3s738409 遗传多态性(OR,1.92;95%CI,1.11-3.33)、低高密度脂蛋白(OR,1.83;95%CI,1.03-3.27)、高甘油三酯(OR,1.48;95%CI,1.18-1.84)、高丙氨酸转氨酶(OR,1.23;95%CI,1.16-1.31)和高铁蛋白血症(OR,1.05;95%CI,1.03-1.07)。两个因素与 AF 相关:高体重指数(OR,1.23;95%CI,1.07-1.42;P=0.005)和高天门冬氨酸转氨酶(OR,1.03;95%CI,1.01-1.05;P=0.001)。使用 MRI-PDFF 作为参考,CAP(最佳截断值 280 dB/m)对中重度脂肪变性的诊断具有良好的准确性(受试者工作特征曲线下面积 0.86;95%CI,0.82-0.90)。
在存在代谢危险因素或不明原因转氨酸升高的 HIV 单一感染者的大型队列中,有三分之二的患者存在脂肪变性,约 10%的患者存在 AF。CAP 技术可准确筛查该人群的脂肪变性。